Neutrophil Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Neutrophil clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Phase 2

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.75 enrolled78 locationsNCT07160608
Recruiting
Early Phase 1

Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaMyeloproliferative Overlap Neoplasms+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins18 enrolled1 locationNCT07071155
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)+1 more
Fate Therapeutics244 enrolled17 locationsNCT06308978
Recruiting
Phase 1

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus ErythematosusLupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07236762
Recruiting
Phase 1

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren's Syndrome (SS)+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07123519
Recruiting
Phase 1

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07104721
Recruiting
Phase 1

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled2 locationsNCT07236801
Recruiting
Early Phase 1

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Rheumatoid ArthritisSystemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
Changhai Hospital60 enrolled1 locationNCT07246096
Recruiting
Phase 4

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Amgen300 enrolled68 locationsNCT06072482
Recruiting
Phase 3

Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisEnd Stage Renal Disease
Centre Hospitalier Departemental Vendee136 enrolled58 locationsNCT03323476
Recruiting

Neutrophils to Lymphocytes and Platelets Ratio, Procalcitonin, and Total Leucocytic Count as Indicators of Prognostic Outcome in Septic Patients in the Intensive Care Unit.

Intensive Care UnitPlateletsNeutrophils to Lymphocytes+4 more
Ain Shams University290 enrolled1 locationNCT07200817
Recruiting

Neutrophil to Lymphocyte Ratio and Postdural Headache

Preoperative Neutrophil-to-Lymphocyte Ratio (NLR)
Istinye University821 enrolled1 locationNCT07075874
Recruiting
Phase 1

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Inflammatory Myopathy+5 more
China Immunotech (Beijing) Biotechnology Co., Ltd.12 enrolled1 locationNCT06978647
Recruiting

Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases

Rheumatoid ArthritisCeliac DiseaseSjogren's Syndrome+6 more
Santé Arménie French-Armenian Research Center800 enrolled6 locationsNCT05904301
Recruiting
Not Applicable

Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)

Clonal Hematopoiesis of Indeterminate PotentialVenous ThrombosesThromboembolic Disease+1 more
University Hospital, Bordeaux150 enrolled7 locationsNCT05711173
Recruiting

Aspirin and Neutrophils in Preeclampsia

PregnancyPreeclampsiaNeutrophil+1 more
Queen Mary University of London60 enrolled1 locationNCT04974892
Recruiting

Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer

Pancreatic Cancer, AdultPerineural InvasionNeutrophil-to-Lymphocyte Ratio+1 more
University of Las Palmas de Gran Canaria323 enrolled1 locationNCT06747481
Recruiting
Phase 1Phase 2

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

Systemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisSjogren's Syndrome+6 more
Essen Biotech75 enrolled1 locationNCT06350110
Recruiting
Not Applicable

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease

Systemic Lupus ErythematosusInflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.6 enrolled1 locationNCT06379646
Recruiting
Phase 1

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

Systemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisIdiopathic Inflammatory Myopathies+1 more
RenJi Hospital48 enrolled1 locationNCT06316076